PRESS-RELEASE filed Aug 5, 2026 at 07:30 ET
Medline reported Q2 2026 adjusted EPS of $0.50, beating consensus of $0.32 by 56%, and revenue of $7.69B, beating $7.51B by 2.3%. Organic sales guidance was raised to 9.0%-10.0% from 8.5%-9.5%, but Adjusted EBITDA guidance was cut to $3.3-$3.4B from $3.5-$3.6B, reflecting inflationary pressure, operational investments, and a $336M fire loss at the Tracy distribution center. The mixed guidance and one-time fire loss temper the strong headline beat.